Article
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
European journal of haematology - 1 Apr 2021
Morabito Fortunato, Tripepi Giovanni, Del Poeta Giovanni, Mauro Francesca Romana, Reda Gianluigi, Sportoletti Paolo, Laurenti Luca, Coscia Marta, Herishanu Yair, Bossio Sabrina, Varettoni Marzia, Murru Roberta, Chiarenza Annalisa, Visentin Andrea, Condoluci Adalgisa, Moia Riccardo, Pietrasanta Daniela, Loseto Giacomo, Consoli Ugo, Scortechini Ilaria, Rossi Francesca Maria, Zucchetto Antonella, Al-Janazreh Hamdi, Vigna Ernesto, Martino Enrica Antonia, Mendicino Francesco, Cassin Ramona, D'Arrigo Graziella, Galimberti Sara, Rago Angela, Angeletti Ilaria, Biagi Annalisa, Del Giudice Ilaria, Bomben Riccardo, Neri Antonino, Fronza Gilberto, Monti Paola, Menichini Paola, Cutrona Giovanna, Jaksic Ozren, Rossi Davide, Di Raimondo Francesco, Cuneo Antonio, Gaidano Gianluca, Polliack Aaron, Trentin Livio, Foà Robin, Ferrarini Manlio, Gattei Valter, Gentile Massimo
Abstract excerpt
OBJECTIVES: To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only. METHODS: A real-life cohort of 675 cases has been identified and investigated in the database of the groups participating in the study. RESULTS: At an unadjusted univariate analysis, a significant death risk reduction was...
Read the complete abstract on PubMed